5 Best Small-Cap Stocks to Buy According to Hedge Funds

4. Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Market Cap: $897 million
Number of Hedge Fund Holders: 30

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a biopharmaceutical company. The company develops molecule therapies that help patients with immune-inflammatory conditions. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was founded in 2012 and is headquartered in Pennsylvania, U.S.

In 2020, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) generated revenue of $6.4 million, up from $4.2 million in 2019. In the second quarter of 2021, the company beat revenue by $0.07 million at $1.82 million. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported a $1.4 million growth in research and development due to the company’s investment in the development of clinical-stage drugs. In July, Jefferies initiated its coverage on Aclaris Therapeutics, Inc. (NASDAQ: ACRS) with a ‘Buy’ rating and a price target of $32. Since the beginning of the year, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has delivered a return of 125.8%.

As of Q1 2021, 30 hedge funds tracked by Insider Monkey have positions in Aclaris Therapeutics, Inc. (NASDAQ: ACRS), up from 23 in the previous quarter. The total value of these stakes is over $655 million.